Clinical Trial Update: Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating talimogene laherparepvec (T-VEC) in unresectable pancreatic cancer has completed. The results were posted in 2016 and the study assesse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Talimogene laherparepvec (talimogene laherparepvec)

Snippet

Sponsor: BioVex Limited | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED | Results posted: 2016-04-15